Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Equi-Bute Paste

This page contains information on Equi-Bute Paste for veterinary use.
The information provided typically includes the following:
  • Equi-Bute Paste Indications
  • Warnings and cautions for Equi-Bute Paste
  • Direction and dosage information for Equi-Bute Paste

Equi-Bute Paste

This treatment applies to the following species:
Manufacturer: RXV

Product Information



NADA #116-087, Approved by FDA.


EQUI-BUTE™ Paste is a synthetic, nonhormonal, anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound’s anti-inflammatory properties.

Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolone derivative, entirely unrelated to the steroid hormones, and has the following structural formula:

Equi-Bute Paste Indications

For the relief of inflammatory conditions associated with the musculoskeletal system in horses.


Use with caution in patients who have a history of drug allergy.


Not for use in horses intended for food.


Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of 2 weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of the appropriate countermeasures.

In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.


Orally - 1 to 2 g of phenylbutazone per 500 lb of body weight, but not to exceed 4 g daily. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.

Guidelines to Successful Therapy:

1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.

2. Response to EQUI-BUTE™ Paste therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.

3. When administering EQUI-BUTE™ Paste the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose.

4. Many chronic conditions will respond to EQUI-BUTE™ Paste therapy, but discontinuance of treatment may result in recurrence of symptoms.


Store at 15°-30°C (59°-86°F).

How Supplied

Syringes containing 12 g of phenylbutazone.


Equi-Bute Paste Caution

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Net wt 25 x 60 g

Each 1 g marking on the plunger contains:


1 g

Made in Ireland.

Manufactured by: Schering-Plough Animal Health

Copyright © 2007, Schering-Plough Animal Health Corp., Summit, NJ 07901.

All rights reserved.

31244218 9/08

NAC No.: 10910710

822 7TH STREET, SUITE 605, GREELEY, CO, 80631
Telephone:   817-859-3000
Every effort has been made to ensure the accuracy of the Equi-Bute Paste information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-01-04